HeyJaredMartta Kelly
- Indexed articles, last 90 days
- 4
- Latest publication
- Sep 11, 2026
- Outlet visibility, for Medscape
- Top 50K sites
- Earliest in this view
- Jul 28, 2026
Latest articles
Global Definition Breaks MI Into Three Clinical Categories (opens the original)
Read excerpt
A new global definition of myocardial infarction (MI) has been devised by a task force of four major cardiology societies, with the goal of enabling cardiologists and other healthcare professionals to better diagnose and treat patients with the condition. The previous universal definition relied on a numerical system that was often challenging to apply to clinical practice, leading to discrepancies in diagnosis and treatment, according to the task force. The updated and simplified classification
Just 20% of Young Adults Have No Risk Factors for CKM (opens the original)
Read excerpt
Almost 80% of young adults were found to have risk factors for cardiovascular-kidney-metabolic (CKM) syndrome by age 23 in a new study, indicating excess adiposity, metabolic risk, and, in some cases, signs of subclinical cardiovascular disease. The findings raise concerns about the possibility of CKM going undetected for years and reiterate the importance of early screening for the condition, the authors said. “We were surprised that only 20% of these young adults had heathy weight, healthy fat
Women Make Up Small Percentage of Trial Leaders for SHD (opens the original)
Read excerpt
Women remain significantly underrepresented in trial leadership roles for interventional structural heart disease (SHD) trials, according to a new study. Less than 10% of committee seats in interventional SHD trials are held by women, while men make up more than half of committees, said Mayra Guerrero, MD, in the Department of Cardiovascular Medicine at Mayo Clinic in Rochester, Minnesota. “Women in the US have historically been underrepresented in cardiovascular medicine, particularly in interv
New Inclisiran Therapy Shows Reduction in LDL Cholesterol (opens the original)
Read excerpt
A novel lipid-lowering therapy, administered twice yearly, showed a significant reduction of elevated low-density lipoprotein cholesterol (LDL-C), a key modifiable risk factor for atherosclerotic cardiovascular disease, according to a new study. Inclisiran, a small interfering RNA targeting hepatic proprotein convertase subtilisin/kexin type 9, led to greater LDL receptor expression and substantial LDL-C reduction, explained the study’s corresponding author, Fellipe Batista, MD, of Centro Edson
Publishing over time
Last 90 days. Choose a month to open its work.
Recurring subjects
Named in the text we hold. One piece can cover several.
Audience
Top 50K sites
For Medscape, the outlet · Measured Aug 1, 2026
Website popularity band, not a count of readers or article views.
About this data
Counts cover the work we have indexed. Tone needs enough text and a confident classification. Excerpts and episode notes are not full articles or transcripts.
Identity or attribution wrong? Suggest a correction.